Hripsime Chomoyan

I am an ophthalmologist who has been doing basic research for the past 3 years. After 5 years as an MD, I realized that I wanted to be involved in the scientific world. I am currently a Research Assistant at Los Angeles Children's Hospital in the Department of Neurosurgery. Along with my skills as an MD and researcher, I always thrive to improve my knowledge of chemistry and biology with courses from MIT. I have (with the number) publications and (with the number) posters for which I am the first author or co-author. I have been associated with the Sarcoma Oncology Research Center in Santa Monica, California, for about 2 years.

I have great aspirations for basic science research and believe my qualifications and goals align with researcher career. My goals are to pursue a PhD in Keck Medical School next year.

• Tumor Diseases of The Eye. Diagnosis and Treatment, Sechenov ClinicA P R I L 2 0 2 2
• ''AAMS's 9th CME Spring Symposium ‑ AAMS'' M AY 2 0 2 2
• GCP for Clinical Trials with Investigational Drugs and Biologics (ICH Focus) M AY 2 0 2 2
• Optical Coherence Tomography (OCT), EYEZONE J A N U A R Y 2 0 2 1
• Armenian Ophthalmology Conference ‑ Armenian EyeCare Projectce M AY 2 0 2 1
• Armenian Ophthalmology Conference ‑ Armenian Young Ophthalmologists Associationce J U N E 2 0 2 1
• Armenian Ophthalmology Conference ‑ Armenian Association of Ophthalmologistsce A U G U S T 2 0 2 1
• Armenian Ophthalmology Conference ‑ Armenian association of Ophthalmologists
  M AY 2 0 2 0
• Armenian Ophthalmology Conference ‑ Armenian Association of Ophthalmology
  J A N U A R Y 2 0 2 0
• Ophthalmology Conference ‑ Armenian EyeCare Project J U LY 2 0 2 0
• Ophthalmology Conference ‑ Armenian Young Ophthalmologists Association M AY 2 0 1 9
• Ophthalmology Conference ‑ Armenian EyeCare Project J U LY 2 0 1 9
• Ophthalmology Conference ‑ Armenian Association of Ophthalmology J A N U A R Y 2 0 1 9
• 4‑th International Conference ‑ Young Doctors Association A U G U S T 2 0 1 8
• 3‑rd International Conference ‑ Young Doctors Association S E P T E M B E R 2 0 1 7

• Chawla SP, Tellez WA, Chomoyan H, Valencia C, Ahari A, Omelchenko N, Makrievski S, Brigham DA, Chua-Alcala V, Quon D, Moradkhani A, Gordon EM. Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311). Front Oncol. 2023 May 10;13:1116937. doi: 10.3389/fonc.2023.1116937. PMID: 37234994; PMCID: PMC10206273.
• Gordon EM, Chawla SP, Tellez WA, Younesi E, Thomas S, Chua-Alcala VS, Chomoyan H, Valencia C, Brigham DA, Moradkhani A, Quon D, Srikureja A, Wong SG, Tseng W, Federman N. SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma. Cancers (Basel). 2023 Jan 31;15(3):906. doi: 10.3390/cancers15030906. PMID: 36765863; PMCID: PMC9913367.
• Gordon EM, Chawla SP, Tellez WA, Younesi E, Thomas S, Chua-Alcala VS, Chomoyan H, Valencia C, Brigham DA, Moradkhani A, Quon D, Srikureja A, Wong SG, Tseng W, Federman N. SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma. Cancers (Basel). 2023 Jan 31;15(3):906. doi: 10.3390/cancers15030906. PMID: 36765863; PMCID: PMC9913367.